Regeneron Pharmaceuticals (REGN) Revenue — Quarter Ended Dec 31, 2023
Regeneron Pharmaceuticals reported higher revenue for the period. Revenue increased relative to both the immediately preceding period and the same period one year earlier.
Key takeaway
Quarter ended Dec 31, 2023 · FY2023 Q4
Regeneron Pharmaceuticals reported higher revenue for the period. Revenue increased relative to both the immediately preceding period and the same period one year earlier.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$3.4B
Revenue reported for this quarter.
Quarter-over-quarter
+2.1%
Change from the immediately preceding quarter.
Year-over-year
+0.6%
Change from the comparable year-ago quarter.
Trailing four quarters
$13.1B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Mar 31, 2023 | $3.2B | +6.6% |
| Jun 30, 2023 | $3.2B | +10.5% |
| Sep 30, 2023 | $3.4B | +14.5% |
| Dec 31, 2023 | $3.4B | +0.6% |
Revenue performance
Revenue for the period rose from the prior period and also from the same period in the previous year. This marks a continuation of the company's revenue growth.
Quarterly comparison
On a sequential basis, revenue increased compared to the prior three-month span. On an annual basis, revenue also exceeded the year-ago level.
What to watch
The company's expansion of manufacturing operations, as highlighted in the filing, may warrant attention in future periods.